Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 8, Pages 752-759
Publisher
American Society of Clinical Oncology (ASCO)
Online
2013-12-03
DOI
10.1200/jco.2013.50.5305
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
- (2017) J. R. Merchan et al. JOURNAL OF CLINICAL ONCOLOGY
- Genitourinary tumors, non-prostate
- (2012) A. Ravaud et al. ANNALS OF ONCOLOGY
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
- (2012) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
- (2012) Ronald Bukowski Cancer Management and Research
- Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
- (2011) Jose Pablo Maroto et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
- (2010) Jesus Rodriguez-Pascual et al. ANTI-CANCER DRUGS
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
- (2008) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
- (2008) B. I. Rini CLINICAL CANCER RESEARCH
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started